Dr. Reddy's Laboratories Ltd.

Financial

	Dr. Reddy's Lab	Mankind Pharma	Lupin
Operational Metrics
API Sector
Global DMFs filed	1199.0 .	n/a	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	354.0 .	60.0 .	430.0 .
Number of ANDA's Approved By USFDA	275.0 .	44.0 .	334.0 .
Domestic Sales Growth - YoY	9.3 %	n/a	7.3 %
R&D as a % of Total Sales	8.0 %	2.15 %	7.7 %
Financials
5 yr Average ROE	14.9 %	23.46 %	2.19 %
5yr average Equity Multiplier	1.41	1.37	1.79
5yr Average Asset Turnover Ratio	0.77	0.95	0.72
5yr Avg Net Profit Margin	14.03 %	17.9 %	1.82 %
Price to Book	3.21	9.62	6.11
P/E	18.38	49.79	33.34
5yr Avg Cash Conversion Cycle	64.1 Days	-44.05 Days	-70.43 Days
Inventory Days	75.39 Days	58.78 Days	51.95 Days
Days Receivable	99.54 Days	24.18 Days	52.75 Days
Days Payable	102.35 Days	130.75 Days	155.88 Days
5yr Average Interest Coverage Ratio	34.06	56.97	3.96
5yr Avg ROCE	19.83 %	30.07 %	8.04 %
5yr Avg Operating Profit Margin	21.19 %	24.6 %	12.57 %
5 yr average Debt to Equity	0.12	0.05	0.34
5yr CAGR Net Profit	22.45 %	13.17 %	n/a
5yr Average Return on Assets	10.71 %	17.12 %	1.4 %
Shareholdings
Promoter Holding	26.64 %	72.7 %	46.92 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.08 %	-3.8 %	0.14 %
Change in Mutual Fund Holding (3 Yrs)	-1.23 %	5.84 %	1.83 %

Business

	Dr. Reddy's Lab	Mankind Pharma	Lupin
Product Wise Break-Up	Product Wise Break-Up Formulations 88.24 Pharmaceutical 9.83 Proprietary 1.93 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 USA 0 Developed Markets 0 NCE licensing income 0 API 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0	Product Wise Break-Up Pain/Analgesics 4.0 Cardiovascular 15.0 Formulations 0 Anti-infectives 14.0 Generic FDF 0 Dermatology 5.0 Urology 2.0 Advanced Markets Formulations 0 API 0 Neuro/CNS 5.0 Respiratory 8.0 Pharmaceutical 0 Custom Synthesis 0 Gastrointestinal 9.0 Gynaecology 10.0 VMN 8.0 Proprietary 0 USA 0 Developed Markets 0 NCE licensing income 0 Anti-Diabetic 9.0 Emerging Market Formulation 0 India 0 Others 11.0	Product Wise Break-Up Pain/Analgesics 0 Cardiovascular 0 Formulations 0 Anti-infectives 0 Generic FDF 0 Dermatology 0 Urology 0 Advanced Markets Formulations 45.0 Active Pharmaceutical Ingredient (API) 9.0 Neuro/CNS 0 Respiratory 0 Pharmaceutical 0 Custom Synthesis 0 Gastro - Intestinal 0 Gynaecology 0 VMN 0 Proprietary 0 USA 0 Developed Markets 0 NCD 1.0 Anti-Diabetic 0 Emerging Market 12.0 India 34.0
Location Wise Break-Up	Location Wise Break-Up USA 48.56 India 17.36 Russia 7.99 Nepal 0 Sri Lanka 0 Bangladesh 0 API 0 EMEA 0 Growth Markets 0 Japan 0 Others 26.09	Location Wise Break-Up EMEA 0 Growth Markets 0 USA 0 Japan 0 Nepal 0 Russia 0 Bangladesh 0 Sri Lanka 0 India 86.0 API 0 Others 14.0	Location Wise Break-Up EMEA 11.0 Developed Markets 8.0 USA 38.0 Japan 0 Nepal 0 Russia 0 Bangladesh 0 Sri Lanka 0 India 34.0 API 5.0 Others 4.0
Operating Profit Break-Up	Operating Profit Break-Up Global Generics 92.18 Pharmaceutical Services and Active Ingredients 4.81 Proprietary Products 3.01	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Oncology 27.53 Central Nervous System (CNS) 12.12 Pain Management 9.77 Gastro Intestinal 9.52 Respiratory 7.04 Cardiac Science 6.65 Anti-Infective 6.48 Others 20.89	-	-
Asset Break-Up	Asset Break-Up India 80.24 Switzerland 8.45 USA 2.37 Others 8.94	-	-

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

SIGN UP FOR FREE